ICON plc | Clinical Research Organisation (CRO) for Drug Development

The key to remarkable rare disease registries

Building trust and collaboration with patient advocacy organisations

Effective participation support strategy is critical to trial efficiency

Critical success factors for rare disease clinical trials

Spotlight on regulatory reforms in China

Although China’s regulatory reforms have attracted many foreign companies to conduct trials in China, there are still challenges.

Environmental, Social & Governance 2021

Translating intent to impact.

Featured Services

Seeking parallel consultation from regulators and HTA bodies in Europe

Market Access

Expertise in mission-critical pricing, market access, and reimbursement.

Site & Patient Solutions

Transforming recruitment through patient-centric trials and real-world, real-time data.

Biotech

ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.

Functional Resourcing

From recruitment of a single clinical professional to managing entire global functions.

Increasing Site and Patient Compliance

FIRECREST: Digital solutions to increase efficiency in clinical trials by driving site performance.

ICON Insights

23 November 2022

Chemistry, manufacturing, and controls in drug development and life cycle management

Chemistry, Manufacturing, and Controls (CMC) is the “first step” to ensuring drug quality throughout the product development lifecycle.

18 November 2022

Understanding the impact of the Clinical Trial Liaison (CTL) function

The impact of the clinical trial liaison function (CTL) in developing and delivering optimal clinical trials.

17 November 2022

Empowering children with education through clinical trials

In support of World Children’s Day 2022, this blog shares strategies to empower children every day through education, specifically in clinical trials.

17 November 2022

A rare partnership: collaborating with patient advocacy organisations for rare disease registries

Rare disease registries: practical ways to build trust and collaboration with patient advocacy groups.

10 November 2022

Keep eCOA off the critical path of clinical trial startup

In today’s patient-driven and competitive drug development landscape, healthcare organizations cannot succeed without active patient insight through COAs.

27 October 2022

Managed Service Providers

Managed Service Providers ensure our businesses have competitive advantage especially in the area of language and translation services.

19 October 2022

Scaling up to CGT commercialisation in a transitioning market

The market for cell and gene therapies (CGTs) is rapidly transitioning from ultra-niche science to approved therapies.

19 October 2022

Best practices for Cell and Gene Therapy manufacturing, handling and delivery

Cell and Gene Therapies (CGTs) offer promising ways to treat previously devastating and intractable diseases.

06 October 2022

Navigating the complexity of CGT clinical trial design

This blog will explore some of the challenges of CGT clinical trial design, such as patient recruitment and data collection, and strategies for how to approach them.

Services

Sectors

Therapeutics

Innovation

Insights

News & Events

About ICON

Healthcare Intelligence

Sponsor and CRO pharmacovigilance and safety alliances

Beyond buzzwords: Diversity, equity and inclusion in rare disease clinical trials

Transfer of marketing authorisation